We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Avanir Settles With Ranbaxy Over Latest Proposed Generic Nuedexta
Avanir Settles With Ranbaxy Over Latest Proposed Generic Nuedexta
Avanir Pharmaceuticals has settled with generic firm Ranbaxy over its bid to produce a version of the brand manufacturer’s Nuedexta, the first drug approved in the U.S. to treat pseudobulbar affect (PBA).